title: Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis.
abstract: OBJECTIVE
  To assess the effects of aromatase inhibitors in women symptomatic of pain with endometriosis.
  
  
  METHODS
  A systematic review of published literature.
  
  
  METHODS
  We conducted a comprehensive literature search to identify all the published observational and randomised studies evaluating the efficacy of aromatase inhibitors on pain associated with endometriosis. A combination of keywords was used to identify the maximum number of relevant citations in MEDLINE, EMBASE, CINAHL and the Cochrane Database. Outcome Pain relief, lesion size and quality of life.
  
  
  RESULTS
  There were eight studies (137 women) evaluating outcomes of aromatase inhibitors. In case series/reports (seven studies, 40 women), aromatase inhibitors combined with progestogens or oral contraceptive pill or gonadotrophin-releasing hormone (GnRH) analogues reduced mean pain scores and lesion size and improved quality of life. An RCT (97 women) demonstrated that aromatase inhibitors in combination with GnRH analogues significantly improved pain (P < 0.0001) compared with GnRH analogues alone together with significant improvement in multidimensional patient scores (P < 0.0001). There was no significant reduction in spine or hip-bone densities.
  
  
  CONCLUSIONS
  Aromatase inhibitors appear to have a promising effect on pain associated with endometriosis, but the strength of this inference is limited due to a dearth of the evidence available.
authors.affiliation: Department of Obstetrics and Gynaecology, Birmingham Women's Hospital, University of Birmingham, Birmingham, UK [corrected]
authors.forename: A
authors.initials: A
authors.lastname: Nawathe
authors.forename: S
authors.initials: S
authors.lastname: Patwardhan
authors.forename: D
authors.initials: D
authors.lastname: Yates
authors.forename: G R
authors.initials: GR
authors.lastname: Harrison
authors.forename: K S
authors.initials: KS
authors.lastname: Khan
mesh_terms: D000700:Analgesics / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D003271:Contraceptive Agents, Female / Q000627:therapeutic use; D004715:Endometriosis / Q000150:complications*; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016912:Levonorgestrel / Q000627:therapeutic use; D017699:Pelvic Pain / Q000188:drug therapy* / Q000209:etiology; D011788:Quality of Life; D011980:Receptors, Progesterone / Q000037:antagonists & inhibitors
chemical_list: D000700:Analgesics; D020533:Angiogenesis Inhibitors; D047072:Aromatase Inhibitors; D003271:Contraceptive Agents, Female; D004965:Estrogen Antagonists; D007155:Immunologic Factors; D011980:Receptors, Progesterone; D016912:Levonorgestrel